Abstract
Primary cytoreductive surgery followed by platinum-based chemotherapy represents the standard treatment for patients with advanced ovarian cancer. But some patients with advanced ovarian cancer still have suboptimal residual disease after the primary debulking surgery. Neoadjuvant chemotherapy has been suggested as an alternative strategy to achieve no residual disease. It is important to find methods to estimate the likelihood that cytoreductive surgery will leave no residual disease. A number of studies have evaluated the use of serologic markers (such as CA-125), imaging modalities (such as CT, PETCT, MRI), and laparoscopic surgery to determine which patients are ideal predictors for neoadjuvant chemotherapy. As a new approach of assessment for preoperative evaluation regarding cytoreduction, laparoscopic surgery deserves further research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Central South University. Medical sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
